Where Do Fractional Lasers Fit in Keratinocyte Carcinoma Prevention? A Clinician-Facing Framework

Background: Fractional lasers have emerging evidence for actinic keratosis (AK) treatment and keratinocyte carcinoma (KC) prevention. The practical guidance for their clinical use remains less clear. Existing studies vary in laser type, treatment settings, PDT protocol, patient population, and follow-up, making it difficult to translate the literature into a usable clinical approach. Objective: To develop a clinician-facing framework for selecting patients and sequencing fractional lasers with field-directed therapy for AKs and field cancerization. Methods: We reviewed 48 manuscripts on fractional laser monotherapy, ablative fractional laser-assisted photodynamic therapy (AFXL-PDT), laser-assisted drug delivery, mechanistic studies, and high-risk populations. Evidence was mapped into a stepwise clinical algorithm. Results: The proposed algorithm first excludes patients with isolated AKs, suspicious lesions requiring biopsy, active infection, poor wound healing risk, or inability to tolerate recovery. Patients with multiple or recurrent AKs, diffuse photodamage, prior KC, or high procedural burden may be considered for fractional laser-based field therapy. AFXL-PDT is favored for thicker lesions, extensive field disease, or immunosuppressed patients, while non-ablative fractional lasers may fit selected patients who prioritize tolerability, cosmetic improvement, and limited downtime. Illumination and incubation choices should reflect the tradeoff between clearance, pain, convenience, and durability. Follow-up at 6–9 months is suggested because field control is not indefinite. Conclusion: Fractional lasers are best viewed as field-directed or adjunctive tools, not replacements for biopsy or standard oncologic care.